Clay Siegall has a diverse education background. He possesses a Ph.D. in genetics and B.S in zoology from George Washington University and the University of Mary Land respectively. Clay Siegall is the president and the CEO of Seattle genetic foundation. Due to his passion for helping the cancer patient, he founded the Seattle genetic company. The company was founded in 1998, and it has being associated with scientific innovation and research on how to fight cancer. Seattle genetic company is the perfect foundation in a century where cancer is growing at an alarming speed.
Since the foundation of Seattle company, Clay Siegall has overseen the growth of the company. In his leadership, he has guided the company from the foundation level to the current stage where it has become a global brand which has being approved in more than 60 nations, all over the world. Seattle genetic company under the leadership of Clay Siegall, it has developed antibody drug conjugates. The company secured an FDA approval on 2011 regarding on its first ADC products.
During the leadership of Clay Siegall, Seattle Company in conjunction with Takeda Pharmaceutical Company have significantly advanced in ADCs cancer treatment. The company has also entered into many licenses on ADCs technology. Seattle genetic technology is significantly used in clinical developments. Clay Siegall has also led Seattle Genetics in money raising activities that have collected approximately $1.2 billion, which include the company’s first public offering in 2001.
Dr. Clay Siegall has more than 70 publications, and he possesses 15 patents. Before founding the Seattle genetic company he worked with National Cancer Institute from 1991 to 1997, he also worked with National Institute of health from 1988 to 1991.Clay Siegall also serves as a board member of several institutes such as Ultralgenyx pharmaceutical, Mirna Therapeutics and also Washington Roundtable.